Table 85Study characteristics for placebo-controlled trials of naloxone

Naloxone
No. trials (Total participants)1 RCT (9)
Study IDsPHILIPSEN2004A
N/% female9/100
Mean age35
Axis I/II disorders56% PTSD; 33% eating disorders; 11% OCD; 22% major depressive disorder; 22% social phobia; 22% specific phobia
Additional interventionNone
SettingInpatients (n = 7); outpatients (n = 2)
Length of treatmentN/A (two injections while patients in dissociative state)
Length of follow-upNone
NotesCross-over trial; data not extractable excluded trial

From: 6, PHARMACOLOGICAL AND OTHER PHYSICAL TREATMENTS IN THE MANAGEMENT OF BORDERLINE PERSONALITY DISORDER

Cover of Borderline Personality Disorder
Borderline Personality Disorder: Treatment and Management.
NICE Clinical Guidelines, No. 78.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009.
Copyright © 2009, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.